bi-907828
boehringer ingelheim
['congrat', 'bi 907828', 'sarcoma', 'boehringer']
#aacr23 mdm2-p53 antagonist bi 907828 bi 907828 currently investigated as first-line treatment for patients with dedifferentiated liposarcoma and other solid cancers. congratulations to an amazing team! 
Global Head of Cancer Research @Boehringer. Focus on improving the lives of cancer patients.